The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-A long-term follow-up study

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 139, Issue 2, 2008, Pages 169-175

  Varma, Rajesh ^a   Soneja, Hemi ^a   Bhatia, Kalsang ^a   Ganesan, Raji ^a   Rollason, Terence ^a   Clark, T Justin ^a   Gupta, Janesh K ^a  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

Endometrial hyperplasia; Intrauterine devices; Levonorgestrel; Medicated; Mirena; Therapy

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; LEVONORGESTREL; TAMOXIFEN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; LONG TERM CARE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTPATIENT; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RELIABILITY; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT INDICATION; UTERUS CANCER;

EID: 47849096862     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.02.022     Document Type: Article

References (32)

1. International Society of Gynaecological Pathologists (ISGP), World Health Organisation (WHO). Classification of endometrial hyperplasia. Blaustein's pathology of the female genital tract. 5th ed. (2002), Springer pp. 467-500
2. Fox H., and Buckley C.H. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology 6 (1982) 493-510
3. Kurman R.J., Kaminski P.F., and Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56 (1985) 403-412
4. Tabata T., Yamawaki T., Yabana T., Ida M., Nishimura K., and Nose Y. Natural history of endometrial hyperplasia. Study of 77 patients. Arch Gynecol Obstet 265 (2001) 85-88
5. Terakawa N., Kigawa J., Taketani Y., et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 23 (1997) 223-230
6. Clark T.J., Neelakantan D., and Gupta J.K. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol. 125 2 (2006) 259-264
7. Montgomery B.E., Daum G.S., and Dunton C.J. Endometrial hyperplasia: a review. Obstet Gynecol Surv 59 5 (2004) 368-378
8. Marsden D.E., and Hacker N.F. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 15 3 (2001) 393-405
9. Wildemeersch D., Janssens D., Pylyser K., et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 57 (2007) 210-213
10. Wheeler D.T., Bristow R.E., and Kurman R.J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 31 (2007) 988-998
11. Varma R., Sinha D., and Gupta J.K. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) - a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 125 (2006) 9-28
12. Perino A., Quartararo P., Catinella E., Genova G., and Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 18 (1987) 137-140
13. Scarselli G., Tantini C., Colafranceschi M., et al. Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol 9 (1988) 284-286
14. Vereide A.B., Kaino T., Sager G., Arnes M., and Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 101 (2006) 214-223
15. Wildemeersch D., and Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 188 (2003) 1297-1298
16. Hejmadi R.K., Chaudhri S., Ganesan R., and Rollason T.P. Morphologic changes in the endometrium associated with the use of the mirena coil: a retrospective study of 106 cases. Int J Surg Pathol 15 (2007) 148-154
17. Horn L.C., Meinel A., Handzel R., and Einenkel J. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol 11 (2007) 297-311
18. Phillips V., Graham C.T., Manek S., and McCluggage W.G. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol 56 (2003) 305-307
19. Kelly P., Dobbs S.P., and McCluggage W.G. Endometrial hyperplasia involving endometrial polyps: report of a series and discussion of the significance in an endometrial biopsy specimen. BJOG 114 (2007) 944-950
20. Altman D.G., and Bland J.M. Diagnostic tests. 1. Sensitivity and specificity. BMJ 308 (1994) 1552
21. Clark T.J., Mann C.H., Shah N., Khan K.S., Song F., and Gupta J.K. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta Obstet Gynecol Scand 80 (2001) 784-793
22. Garuti G., Cellani F., Garzia D., Colonnelli M., and Luerti M. Accuracy of hysteroscopic diagnosis of endometrial hyperplasia: a retrospective study of 323 patients. J Minim Invasive Gynecol 12 (2005) 247-253
23. Gundem G., Sendag F., Kazandi M., et al. Preoperative and postoperative correlation of histopathological findings in cases of endometrial hyperplasia. Eur J Gynaecol Oncol 24 (2003) 330-333
24. Lambert B., Muteganya D., Lepage Y., and Boivin Y. Complex hyperplasia of the endometrium. Predictive value of curettage vs. hysterectomy specimens. J Reprod Med 39 (1994) 639-642
25. Jesadapatrakul S., Tangjitgamol S., and Manusirivitaya S. Histopathologic consistency between endometrial hyperplasia diagnosis from endometrial curettage and pathologic diagnoses from hysterectomy specimens. J Med Assoc Thai 88 suppl. 2 (2005) S16-S21
26. Rattanachaiyanont M., Angsuwathana S., Techatrisak K., Tanmahasamut P., Indhavivadhana S., and Leerasiri P. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res 31 (2005) 98-106
27. Horn L.C., Schnurrbusch U., Bilek K., Hentschel B., and Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 14 (2004) 348-353
28. Ferenczy A., and Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160 (1989) 126-131
29. Randall T.C., and Kurman R.J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90 (1997) 434-440
30. Perez-Medina T., Bajo J., Folgueira G., Haya J., and Ortega P. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up. Gynecol Oncol 73 (1999) 299-304
31. Jarvela I.Y., and Santala M. Treatment of non-atypic endometrial hyperplasia using thermal balloon endometrial ablation therapy. Obstet Gynecol Surv 60 (2005) 580-582
32. Agorastos T., Vaitsi V., Pantazis K., Efstathiadis E., Vavilis D., and Bontis J.N. Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women. Eur J Obstet Gynecol Reprod Biol 118 (2005) 239-240